{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:38:23Z","timestamp":1759588703272,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"1-2","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is the most effective treatment for carcinoma in situ and high-risk non-muscle invasive bladder cancer (NMIBC). However, it can also provoke diverse side effects. We found 1 patient with a significantly and rapidly reduced bladder volume after the instillation of BCG. Few such cases and corresponding treatments have been reported. We speculated that the tuberculosis infection existed, so antitubercular therapy was given. After a 3-month oral intake of rifampicin, isoniazid, and ofloxacin, the volume of bladder returned to normal and the voiding symptoms disappeared. This case indicated that the reduction of bladder volume caused by BCG instillation could be treated with antitubercular therapy. Prompt and accurate diagnosis was important for the management. <\/jats:p>","DOI":"10.1159\/000510167","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T21:00:34Z","timestamp":1599166834000},"page":"155-158","source":"Crossref","is-referenced-by-count":3,"title":["Reduction of Bladder Volume after BCG Immunotherapy"],"prefix":"10.1159","volume":"105","author":[{"given":"Changzhao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengtong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"ref1","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ): 2019 Update. <X00_Journal>Eur Urol<\/X00_Journal>. 2019;76(5):639\u201357."},{"key":"ref2","unstructured":"Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. <X00_Journal>Eur Urol<\/X00_Journal>. 2000;37(Suppl 1):33\u20136."},{"key":"ref3","unstructured":"Bohle A, Balck F, von Weitersheim J, Jocham D. The quality of life during intravesical bacillus Calmette-Guerin therapy. <X00_Journal>J Urol<\/X00_Journal>. 1996;155(4):1221\u20136."},{"key":"ref4","unstructured":"Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. <X00_Journal>J Urol<\/X00_Journal>. 1992;147(3):596\u2013600."},{"key":"ref5","unstructured":"Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. <X00_Journal>J Urol<\/X00_Journal>. 2006;176(3):935\u20139."},{"key":"ref6","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. <X00_Journal>Eur Urol<\/X00_Journal>. 2014;65(1):69\u201376."},{"key":"ref7","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. <X00_Journal>Eur Urol<\/X00_Journal>. 2013;63(3):462\u201372."},{"key":"ref8","unstructured":"Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. <X00_Journal>Eur Urol Suppl<\/X00_Journal>. 2008;7(10):667\u201374."},{"key":"ref9","unstructured":"Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, Lee MH, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. <X00_Journal>Int J Urol<\/X00_Journal>. 2016;23(7):542\u20139."},{"key":"ref10","unstructured":"van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal. <X00_Journal>Eur Urol<\/X00_Journal>. 2008;53(1):60\u20137."},{"key":"ref11","unstructured":"Garcia C, Jina H, Bergersen P, Chalasani V. Bladder contracture: a rare and serious side effect of intravesical bacillus Calmette-Gu\u00e9rin therapy. <X00_Journal>Urol Case Rep<\/X00_Journal>. 2015;4:22\u20134."},{"key":"ref12","unstructured":"Numakura K, Tsuchiya N, Tsuruta H, Akihama S, Saito M, Inoue T, et al. Efficacy and safety of bladder hydrodistension for decreased bladder capacity induced by intravesical BCG therapy. <X00_Journal>Scand J Urol<\/X00_Journal>. 2016;50(6):429\u201332."},{"key":"ref13","unstructured":"Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. <X00_Journal>J Urol<\/X00_Journal>. 1999;161(5):1568\u20139."}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:54:02Z","timestamp":1745423642000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000510167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":13,"journal-issue":{"issue":"1-2","published-online":{"date-parts":[[2021,1,20]]},"published-print":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.1159\/000510167","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"type":"print","value":"0042-1138"},{"type":"electronic","value":"1423-0399"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}